That hasn't been the mandate of this working group. A lot of the working group itself is focusing more on the fact that there is a lot of research happening out there in the field when you're looking at post-marketing surveillance or post-market studies, so how do you collaborate and form networks of those studies?
On the progressive licensing framework, we've been speaking to Health Canada individually, as jurisdictions, through some of the consultations they've been doing, and that has been through a different vehicle. It has not been through the national pharmaceutical strategy.